Medical Research
Factlen Research
Landmark Phase 3 Trial: New Oral GLP-1 Pill Orforglipron Outperforms Semaglutide for Weight Loss and Diabetes Control
4 sources · 16d ago
Factlen Research
First-in-Class NDSRI Centanafadine Poised to Reshape ADHD Treatment for All Ages
6 sources · 17d ago
Factlen Explainer
Landmark Immunotherapy Trial Achieves 33% Three-Year Survival in Previously Untreatable MSS Colorectal Cancer
4 sources · 18d ago
More in Medical Research
Factlen ExplainerOrexin Agonists
First-in-Class Orexin Agonist Oveporexton Shows Significant Improvement in Wakefulness for Narcolepsy Type 1 in Landmark Phase 3 Trials
Sleep Medicine Researchers 41%Patients & Advocacy Groups 35%Industry Analysts 24%
4 sources · 18d ago
Factlen ExplainerLung Cancer Therapy
Landmark Trial: Bispecific Antibody Ivonescimab Achieves 34% Survival Advantage Over Standard Immunotherapy in Lung Cancer
Clinical Oncologists 40%Biopharma Analysts 35%Evidence Skeptics 25%
4 sources · 18d ago
Factlen ExplainerBundibugyo Virus
WHO Launches Landmark Global Trial to Find First Effective Treatments for Bundibugyo Virus
Global Health Authorities 35%Clinical Researchers 35%Frontline Responders 29%
5 sources · 19d ago
Factlen ExplainerAlzheimer's Biomarkers
Landmark Study: Circular RNA Blood Test Outperforms Gold Standard in Predicting Alzheimer's Progression
Diagnostic Innovators 45%Clinical Trialists 35%Cautious Methodologists 20%
3 sources · 19d ago
Factlen ResearchRenal Cell Carcinoma
FDA Approves Belzutifan and Pembrolizumab Combination as New Standard for High-Risk Kidney Cancer
Clinical Oncologists 45%Clinical Trial Investigators 35%Regulatory Authorities 20%
4 sources · 19d ago
Factlen ResearchOncology Breakthrough
Landmark Trial Adds Immunotherapy to Chemo, Halving Recurrence Risk in Stage III dMMR Colon Cancer
Clinical Oncologists 40%Patient Advocacy Groups 30%Regulatory & Industry Analysts 30%
5 sources · 20d ago
Factlen ExplainerHER2 Therapies
FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer, Signaling New Standard of Care
Clinical Researchers 47%Regulatory Monitors 35%Industry Analysts 18%
5 sources · 21d ago
Factlen ResearchPrecision Immunology
First-in-Class Extracellular Protein Degrader Enters Phase 3 to Target Root Cause of Graves' Disease
Clinical Trial Investigators 41%Targeted Protein Degradation Pioneers 29%Biotech Industry Analysts 29%
6 sources · 21d ago
Factlen ResearchMantle Cell Lymphoma
Landmark Phase 3 Trial Establishes Chemotherapy-Free Regimen as New Standard for Frontline Mantle Cell Lymphoma
Clinical Hematologists 41%Patient Advocates 29%Regulatory Analysts 29%
5 sources · 22d ago
Factlen ExplainerBreast Cancer
Landmark Study Finds Intraoperative PET-CT Significantly Reduces Re-Operation Rates in Breast-Conserving Surgery
Surgical Oncologists 40%Radiology & Imaging Experts 35%Patient Advocates & Trialists 25%
5 sources · 22d ago
Factlen ResearchPrecision Medicine
NIH's All of Us Program Unveils World's Largest Integrated Genomic and Clinical Dataset for Precision Medicine
Precision Medicine Researchers 40%Health Equity Advocates 35%Medical Informaticians 25%
4 sources · 23d ago
Factlen ExplainermRNA Vaccines
Personalized mRNA Cancer Vaccines Advance to Phase 3 Trials for Pancreatic Cancer and Melanoma
Clinical Oncologists 40%Biotech Developers 35%Evidence Analysts 25%
3 sources · 24d ago
Factlen ExplainerGLP-1 Therapeutics
The Evidence Pack: How Semaglutide Significantly Improves Outcomes in Hard-to-Treat Heart Failure
Clinical Cardiologists 45%Cardiovascular Researchers 35%Health Economists 20%
4 sources · 24d ago